Rafael (NYSE:RFL) Announces Earnings Results

Rafael (NYSE:RFL) issued its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.24 million during the quarter. Rafael had a negative return on equity of 39.52% and a negative net margin of 3,390.73%.

Rafael Price Performance

Rafael stock traded down $0.03 during midday trading on Friday, reaching $1.09. The company’s stock had a trading volume of 67,242 shares, compared to its average volume of 72,806. The stock has a market capitalization of $56.94 million, a P/E ratio of -1.89 and a beta of 0.35. The stock’s 50-day simple moving average is $1.84 and its 200-day simple moving average is $1.69. Rafael has a 52-week low of $1.08 and a 52-week high of $3.96.

Hedge Funds Weigh In On Rafael

An institutional investor recently bought a new stake in Rafael stock. Kahn Brothers Group Inc. acquired a new stake in Rafael Holdings, Inc. (NYSE:RFL) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 58,557 shares of the company’s stock, valued at approximately $73,196,000. Rafael makes up 0.1% of Kahn Brothers Group Inc.’s holdings, making the stock its 13th biggest holding. Kahn Brothers Group Inc. owned 0.11% of Rafael as of its most recent SEC filing. Institutional investors own 11.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RFL. Weiss Ratings reissued a “sell (d-)” rating on shares of Rafael in a research note on Tuesday, August 25th. Wall Street Zen raised Rafael to a “hold” rating in a report on Saturday, July 25th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Rafael

Rafael Holdings, Inc (NYSE:RFL) is a diversified holding company with interests in biotechnology and commercial real estate. Through its life sciences operations, the company has focused on developing potential treatments for cancer and other serious diseases, including therapies designed to target the metabolism of cancer cells.

Rafael’s biotechnology activities have been conducted primarily through Rafael Pharmaceuticals, which has researched investigational drug candidates such as devimistat (also known as CPI-613).